

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, ALK (ALKB:DC / OMX: ALK B) hereby announces that Arbejdsmarkedets Tillægspension ("ATP") (The Danish Supplementary Labour Market Pension) has informed ALK that ATP has reduced its ownership in ALK to below 5% of the share capital (previously 5.0%). The notification (in Danish) from ATP is attached to this company release.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Maiken Riise Andersen, tel. +45 5054 1434

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. ALK manufactures and markets allergy immunotherapy ('AIT') treatments, acute anaphylaxis treatments, and other products and services for doctors and people with allergy. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Direktionen

ALK-Abelló A/S
Bøge Alle 6-8
2970 Hørsholm

Email: ppidk@alk.net

19. december 2025

ATP-31-05-071

ATP
Kongens Vænge 8
3400 Hillerød

Storaktionærmeddelelse - Reduktion af ejer- og stemmeandel.

Tlf.: 70 11 12 13
Fax: 48 20 48 00
atp@atp.dk
www.atp.dk
CVR-nr.: 43405810

Arbejdsmarkedets Tillægspension ("ATP") giver hermed i medfør af kapitalmarkedslovens § 38, stk. 1, meddelelse til ALK-Abelló A/S om, at ATP's besiddelse af aktier i ALK-Abelló A/S den 19. dec. 2025 udgør 4,99% af aktiekapitalen og 2,75% af stemmerettighederne i ALK-Abelló A/S.

Telefontid:
Man-tors: 8.00-16.00
Fredag: 8.00-15.30

Med venlig hilsen

Emile K. Marshall
ATP, Senior Portfolio Manager

N.B.

Denne meddelelse er ligeledes sendt til Finanstilsynet